Androgen Receptor Inhibitors in the Treatment of Acne Vulgaris: Efficacy and Safety Profiles of Clascoterone 1% Cream

This narrative review summarized clinical trials on the efficacy and safety of clascoterone 1% cream (Winlevi) for treating acne vulgaris. Clascoterone 1% cream represented a novel topical antiandrogen medication, offering a promising new treatment approach for this common skin condition. As the first topical androgen antagonist, it was expected to encourage further research into other androgen receptor antagonists with potentially similar or improved efficacy.